138 related articles for article (PubMed ID: 18162986)
1. Pharmacodynamics of rituximab in kidney transplantation.
Genberg H; Hansson A; Wernerson A; Wennberg L; Tydén G
Transplantation; 2007 Dec; 84(12 Suppl):S33-6. PubMed ID: 18162986
[TBL] [Abstract][Full Text] [Related]
2. Rituximab removes intrarenal B cell clusters in patients with renal vascular allograft rejection.
Steinmetz OM; Lange-Hüsken F; Turner JE; Vernauer A; Helmchen U; Stahl RA; Thaiss F; Panzer U
Transplantation; 2007 Oct; 84(7):842-50. PubMed ID: 17984836
[TBL] [Abstract][Full Text] [Related]
3. Anti-CD20 treatment depletes B-cells in blood and lymphatic tissue of cynomolgus monkeys.
Schröder C; Azimzadeh AM; Wu G; Price JO; Atkinson JB; Pierson RN
Transpl Immunol; 2003; 12(1):19-28. PubMed ID: 14551029
[TBL] [Abstract][Full Text] [Related]
4. Pharmacodynamics of rituximab in kidney allotransplantation.
Genberg H; Hansson A; Wernerson A; Wennberg L; Tydén G
Am J Transplant; 2006 Oct; 6(10):2418-28. PubMed ID: 16925569
[TBL] [Abstract][Full Text] [Related]
5. Impact of low-dose rituximab on splenic B cells in ABO-incompatible renal transplant recipients.
Toki D; Ishida H; Horita S; Setoguchi K; Yamaguchi Y; Tanabe K
Transpl Int; 2009 Apr; 22(4):447-54. PubMed ID: 19144092
[TBL] [Abstract][Full Text] [Related]
6. Effect of rituximab on the peripheral blood and cerebrospinal fluid B cells in patients with primary progressive multiple sclerosis.
Monson NL; Cravens PD; Frohman EM; Hawker K; Racke MK
Arch Neurol; 2005 Feb; 62(2):258-64. PubMed ID: 15710854
[TBL] [Abstract][Full Text] [Related]
7. Refractory acute kidney transplant rejection with CD20 graft infiltrates and successful therapy with rituximab.
Alausa M; Almagro U; Siddiqi N; Zuiderweg R; Medipalli R; Hariharan S
Clin Transplant; 2005 Feb; 19(1):137-40. PubMed ID: 15659147
[TBL] [Abstract][Full Text] [Related]
8. B cell survival in intragraft tertiary lymphoid organs after rituximab therapy.
Thaunat O; Patey N; Gautreau C; Lechaton S; Fremeaux-Bacchi V; Dieu-Nosjean MC; Cassuto-Viguier E; Legendre C; Delahousse M; Lang P; Michel JB; Nicoletti A
Transplantation; 2008 Jun; 85(11):1648-53. PubMed ID: 18551073
[TBL] [Abstract][Full Text] [Related]
9. Use of rituximab in focal glomerulosclerosis relapses after renal transplantation.
Dello Strologo L; Guzzo I; Laurenzi C; Vivarelli M; Parodi A; Barbano G; Camilla R; Scozzola F; Amore A; Ginevri F; Murer L
Transplantation; 2009 Aug; 88(3):417-20. PubMed ID: 19667947
[TBL] [Abstract][Full Text] [Related]
10. B cell monitoring of transplant patients treated with anti-CD20.
Abdallah KO; Prak ET
Clin Transpl; 2006; ():427-37. PubMed ID: 18365400
[TBL] [Abstract][Full Text] [Related]
11. Reconstitution of peripheral allospecific CD19+ B-cell subsets after B-lymphocyte depletion therapy in renal transplant patients.
Kopchaliiska D; Zachary AA; Montgomery RA; Leffell MS
Transplantation; 2009 May; 87(9):1394-401. PubMed ID: 19424042
[TBL] [Abstract][Full Text] [Related]
12. Rituximab as monotherapy for elicited xenoreactive antibody responses.
Gonzalez-Stawinski GV; Davis RD
J Heart Lung Transplant; 2006 Dec; 25(12):1462-6. PubMed ID: 17178342
[TBL] [Abstract][Full Text] [Related]
13. The role of complement in the therapeutic activity of rituximab in a murine B lymphoma model homing in lymph nodes.
Golay J; Cittera E; Di Gaetano N; Manganini M; Mosca M; Nebuloni M; van Rooijen N; Vago L; Introna M
Haematologica; 2006 Feb; 91(2):176-83. PubMed ID: 16461301
[TBL] [Abstract][Full Text] [Related]
14. Variability in the biological response to anti-CD20 B cell depletion in systemic lupus erythaematosus.
Albert D; Dunham J; Khan S; Stansberry J; Kolasinski S; Tsai D; Pullman-Mooar S; Barnack F; Striebich C; Looney RJ; Prak ET; Kimberly R; Zhang Y; Eisenberg R
Ann Rheum Dis; 2008 Dec; 67(12):1724-31. PubMed ID: 18250115
[TBL] [Abstract][Full Text] [Related]
15. The emerging role of rituximab in organ transplantation.
Becker YT; Samaniego-Picota M; Sollinger HW
Transpl Int; 2006 Aug; 19(8):621-8. PubMed ID: 16827678
[TBL] [Abstract][Full Text] [Related]
16. Cytomegalovirus infection following renal transplantation in patients administered low-dose rituximab induction therapy.
Nishida H; Ishida H; Tanaka T; Amano H; Omoto K; Shirakawa H; Shimizu T; Iida S; Toki D; Yamaguchi Y; Tanabe K
Transpl Int; 2009 Oct; 22(10):961-9. PubMed ID: 19619177
[TBL] [Abstract][Full Text] [Related]
17. Rituximab-induced changes in hematolymphoid tissues found at autopsy.
Cioc AM; Vanderwerf SM; Peterson BA; Robu VG; Forster CL; Pambuccian SE
Am J Clin Pathol; 2008 Oct; 130(4):604-12. PubMed ID: 18794054
[TBL] [Abstract][Full Text] [Related]
18. Bone marrow B-lineage cells in patients with rheumatoid arthritis following rituximab therapy.
Leandro MJ; Cooper N; Cambridge G; Ehrenstein MR; Edwards JC
Rheumatology (Oxford); 2007 Jan; 46(1):29-36. PubMed ID: 16735454
[TBL] [Abstract][Full Text] [Related]
19. In vivo human B-cell subset recovery after in vivo depletion with rituximab, anti-human CD20 monoclonal antibody.
Sidner RA; Book BK; Agarwal A; Bearden CM; Vieira CA; Pescovitz MD
Hum Antibodies; 2004; 13(3):55-62. PubMed ID: 15598985
[TBL] [Abstract][Full Text] [Related]
20. Residual inflammation after rituximab treatment is associated with sustained synovial plasma cell infiltration and enhanced B cell repopulation.
Teng YK; Levarht EW; Toes RE; Huizinga TW; van Laar JM
Ann Rheum Dis; 2009 Jun; 68(6):1011-6. PubMed ID: 18647852
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
